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COMPARISON OF TWO REDUCED INTENSITY ALLOGENEIC PERIPH-
ERAL BLOOD STEM TRANSPLANT CONDITIONING REGIMENS
Raﬂores, M.B., Rossetti, J.M., Shadduck, R.K., Lister, J. Western
Pennsylvania Hospital, Pittsburgh, PA.
We retrospectively compared treatment related mortality
(TRM), overall survival (OS), disease free survival (DFS) and
incidence of acute graft versus host disease (GVHD) of 2 reduced
intensity conditioning regimens (RICR) for sibling allogeneic pe-
ripheral blood stem cell transplantation in patients with poor risk
hematological malignancy. The original RICR, regimen A, con-
sisted of ﬂudarabine 30 mg/m2 (day 5 to day 2), melphalan
140-180 mg/m2 (day 3) and ethyol 910 mg/m2 (day 3) with
mycophenolate mofetil 1 g q12h and tacrolimus (serum level 5-15
ng/ml beginning day 3) as immunosuppressive therapy. Modiﬁ-
cations in regimen B included the use of a lower dose of melphalan
(100 mg/m2), and the addition of Thymoglobulin 2 mg/kg/d (day
2 to day 0). The method of Kaplan and Meier was used to
compare OS and DFS with the log rank test. The cumulative inci-
dence of TRM and acute GVHD in each group was compared using
the Pearson chi square method. Results: 25 patients were trans-
planted in A with median age of 47 years (range 19-65). 22 patients
were transplanted in B with median age of 44 years (range 18-68).
The cumulative incidence of grade 2-4 acute GVHD in patients
not receiving donor lymphocyte infusion (DLI) and alive for more
than 30 days post transplant was signiﬁcantly reduced in regimen B
(A 70%, B 6%; P .002). There was no signiﬁcant difference
at 1 year in OS (A  45%, B  40%; P  .70), DFS (P  .40) and
TRM (P  .40) between the two groups. Conclusion: Despite a
marked decrease in acute GVHD incidence with the addition of
Thymoglobulin and lowering of the melphalan dose in regimen B,
there was no decrease in TRM. Conversely, DFS was not worsened
by these changes suggesting no difference in efﬁcacy between the
two regimens. A decreased incidence of GVHD seems nonetheless
preferable and regimen B forms the basis for future investigation.
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UNRELATED CORD BLOOD TRANSPLANTATION—A SINGLE COLOM-
BIAN HOSPITAL EXPERIENCE
Cue´llar-Ambrosi, F.1,2, Quevedo-Ve´lez, A.1,2, Duque-Martelo, J.I.1,
Cuervo-Sierra, J.1, Sarmiento-Maldonado, M.1,2, Torres-Hernandez, J.D.1,2,
Vizcarra-Reyes, F.1,2, Vela´squez-Lopera, M.1,3, Calle-Fernandez, S.1,
Garcı´a, L.F.3, Rubinstein, P.4 1. Unidad de Trasplantes de Sangre y
Me´dula Osea-Hospital San Vicente de Pau´l, Medellı´n, Colombia; 2.
Facultad de Medicina, Universidad de Antioquia, Medellı´n, Colombia; 3.
Grupo de Inmunologı´a Celular e Inmunogene´tica, Facultad de Medicina,
Universidad de Antioquia, Medellı´n, Colombia; 4. F.H. Allen Labora-
tory of Immunogenetics and National Cord Blood Program, New York
Blood Center, New York, NY.
In recent years, umbilical cord blood (UCB) has emerged as a
feasible alternative source of hematopoietic progenitors (CD34)
for allogeneic stem cell transplantation, mainly in patients who lack
HLA-matched related marrow donors. Since the ﬁrst unrelated
donor transplant in 1993 more than 3500 patients have received
unrelated UCB transplants for a variety of malignant and non-
malignant diseases. At the Hospital San Vicente de Pau´l in Medel-
lı´n,Colombia, 12 patients, 10 children and two adults have been
transplanted with unrelated UCB since 2001. 8 patients had no-
malignant bone marrow diseases and 4 had malignant diseases.
Median age was 9.5 years (1-28). Unrelated UCB units were
provided by The New York Blood Center. Nine cord units were
HLA-matched 4/6, two 5/6 and three 6/6. Two adults received
more than one unit. Conditioning regimens were non-myeloabla-
tive in 4 cases and in 8 busulfan-cyclophosphamide-ATG/ TBI-
cyclophosphamide-ﬂudarabine-ATG. The median cryopreserved
nucleated cell dose in children was 67.6  106 (35.7-165.7  106)
and in the adult patients 42.1  106 (30-54.1  106). Engraftment
occurred in 7/10 of the assessable cases (70%). Median time of
neutrophil and platelet recovery (ANC 	500/dl and PTL
	20000/dl untransfused) was 24 days (19-34) and 35 days (28-58)
respectively. Of the recipients who engrafted, 2/7 (28%) patients
developed aGvHD grade 0-II and one (14%) grade III-IV. One of
these patients had limited cGvHD. Full chimerism was detected in all
alive patients day 100 but one who had acquired aplastic anemia
with initial autologous recovery and late relapse. Median follow-up
time was 22 months (6-54 months). 5/12 (42%) of patients are alive
and in good conditions. Treatment related mortality occurred in 4/12
(30%) of the cases, 2 patients died due to relapse and one of dissem-
inated M. bovis BCG infection on day 243. Although limited, this
experience is encouraging and demonstrates that UCB transplanta-
tion is feasible in developing countries such as Colombia and corre-
lated with the previously reported data.
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POST-ENGRAFTMENT INFECTIONS IN ADULT PATIENTS TRANS-
PLANTED WITH SINGLE CORD BLOOD UNITS SUPPORTED BY CO-
INFUSION OF MOBILIZED PURIFIED HEMATOPOIETIC STEM CELLS
FROM A THIRD PARTY DONOR
Cabrera, R., Krsnik, I., Fore´s, R., Ruiz, E., Bautista, G., Navarro, B.,
Gayoso, J., Gil, S., Regidor, C., Sanjuan, I., Ojeda, E.,
Garcı´a-Marco, J.A., Ferna´ndez, M.N. Hematology, Hospital Puerta de
Hierro UAM, Madrid, Spain.
We have co-infused mobilized puriﬁed hematopoietic stem cells
from a third party donor to shorten neutropenia in single unit cord
blood transplantation (CBT). We describe post-engraftment in-
fections in 33 adults (22 male, median age 30, range 16-59) with
high-risk hematological diseases. Pre-CBT serology was: toxo-
plasma 12 positive/13 negative (4 received HSC from a seroposi-
tive donor)/8 unknown; 30 were positive for CMV. Seven patients
were HBsAb(), HBsAg() and 1 HBsAg() HBsAb(). ANC
	500/L was achieved by 32/33, median time 10 days (9-36) and
full CB chimerism by 32/33 cases. Most signiﬁcant infections
occurred after ANC recovery. There were 34 episodes of CMV
reactivation (3 deaths day 60 of CMV pneumonitis). Of 3
patients with CNS toxoplasmosis (2 sero pre-CBT), 1 died as a
result (day 70), 1 of acute GVHD (120) and 1 is alive on
Fansidar (570). One patient had visceral leishmaniasis (day180)
(BM aspirate for FUO; alive on amphotericin, day 410).Seven
patients developed hemorrhagic cystitis, 6 related to polyomavirus
(PCR on urine): 4 resolved with no treatment, 2 with cidofovir or
leﬂunomide, one had asymptomatic viruria. HBsAg reappeared in
3/7 HbsAb() HBsAg() patients (1 asymptomatic, 1 acute hep-
atitis and 1 cirrhosis). A HBsAg() patient was uneventfully trans-
planted on adefovir. Eight late (	120) episodes of HZV were
seen. A 27-year-old Spaniard died (day 39) of trypanosomiasis (BM
aspirate for FUO, positive PCR). Activation of pre-CBT transfusion-
related infection is suspected. CBT recipients suffer a high number of
non-bacterial post-engraftment infections, which seem related to de-
layed recovery of cell-mediated immunity. CMV heads the list but
early diagnostic techniques and antivirals are available. Our toxo-
plasma cases have prompted us to use prophylaxis in seropositive
patients. HBV reactivation among HBsAb() HBsAg() patients
raises the issue of prophylaxis during CBT versus serological moni-
toring and pre-emptive therapy. Leishmaniasis is endemic among our
dogs, so we search for it in FUO (BM examination and culture).
Polyomavirus viruria (50% of BMT recipients) precedes symptoms
but the value of prospective monitoring and antivirals is unknown.
CBT infections require wide pre-BMT screening, close analytical and
clinical monitoring, prophylactic/preemptive strategies or early ag-
gressive therapy and innovative immunotherapeutic approaches.
Grants PI04/2794 Allostem.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PA-
TIENTS OVER 50: THE SINGLE CENTRE EXPERIENCE
Cetkovsky, P., Vitek, A., Pohlreich, D., Zajickova, M., Markova, M.,
Valkova, V., Cermak, J., Maaloufova, J., Kouba, M., Soukup, P.,
Klener, P. Institute of Hematology and Blood Transfusion, Prague, Czech
Republic.
Introduction: Hematopoietic stem cell transplantation (HSCT)
is an effective treatment modality, but it is associated with signif-
icant morbidity and mortality, especially in older patients (pts)
following myeloablative regimens (MY). For this reason an age
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limit is frequently set (usually 40-55 years). Nonetheless, advances
in transplantology and supportive care in recent years have allowed
for the age limit to be extended. The current limit at our institute
is 65 years (we evaluate not only the so-called calendar age, but also
the “biological” age). Seeing that transplant indications in patients
aged 50-65 remain controversial, we conducted the following anal-
ysis. Patients: 70 pts that underwent HSCT between 2001-2005
were evaluated, median age 57 (50-34) years, 45 men and 25
women. 38 pts underwent MY HSCT and 32 reduced intensity
conditioning (RIC). Bone marrow was used as the graft in 8 cases,
peripheral stem cells in 62. A sibling was the donor in 31 cases (2
another relative), a matched unrelated donor in 22 and a mis-
matched unrelated donor in 15 cases. Diagnosis: AML, CML,
MDS, NHL, CLL, solid tumours, myeloproliferative disease. Re-
sults: Overall 49 pts (70%) survive for 31 (3-54) months. 21 (30%)
pts have died: 15 (21%) from transplant-related mortality (TRM),
4 (6%) from relapse. 21 (66%) of pts undergoing RIC survive, 7
(22%) died of TRM, 2 (6%) died of relapse. 27 (71%) of pts
undergoing MY survive. 8 (21%) died of TRM and 2(5%) died of
relapse. Of the 24 pts aged 55-59 undergoing MY (n  12), 8
(67%) survive and the TRM is 25%, while in the same age under-
going RIC (n  12), 7 (58%) survive and the TRM is 33%. Of the
13 pts aged 60-65 undergoing MY (n  3), all survive, while in the
same age group undergoing RIC (n  10) 5 (50%) survive and the
TRM is 40%. Conclusions: The authors believe that no patient
should be excluded from the allogeneic HSCT program because of
age if he/she meets other criteria, e.g. disease type and stage, no
active infection or organ dysfunction, adequate general state of
health and biological age not exceeding calendar age. These con-
clusions are supported by the results of the analysis presented here,
which showed that even in the category of 60-65 years over 30% of
patients survive long-term. This study was supported with a grant
from Czech Ministry of Health IGA NR/8223-3.
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A STUDY COMPARING VARIABLE NUMBER OF TANDEM REPEAT
(VNTR) LOCI-ANALYSIS AND SHORT TANDEM REPEAT (STR)-BASED
ASSAY IN THE ASSESSMENT OF CHIMAERISM POST ALLOGENEIC STEM
CELL TRANSPLANT AND PREDICTION OF REMISSION/RELAPSE
Koh, M.B.C.1,2, How, G.F.1, Koh, M.1, Tan, W.F.2, Lim, L.C.1,
Koh, L.P.1, Tan, S.Y.1 1. Singapore General Hospital, Singapore,
Singapore; 2. Health Sciences Authority, Singapore, Singapore.
It has been documented that the continuing presence of mixed
chimaerism post allogeneic stem cell transplantation is associated
with a higher incidence of disease relapse. Chimaerism status is
even more crucial in non myeloablative regimens in order to guide
post transplant immunotherapy. Variable number of tandem re-
peats (VNTRs) and short tandem repeats (STRs) are the most
common techniques used in chimaerism analysis. A prospective
study was performed to assess chimaerism in 91 recipient samples
collected over a 7-month period at our institution. Samples were
analysed by both VNTR analysis and a STR-based assay. These
samples were tested in a blinded fashion. The purpose was to
compare sensitivity of the 2 methods and clinical correlation with
transplant outcome. Our current method of chimaerism detection
employs the use of ﬁve highly polymorphic VNTR loci to screen
the pretransplant recipient and donor DNA samples. The most
informative and sensitive locus was used for engraftment monitor-
ing. In sex-mismatched BMTs with a female graft donor, ampliﬁ-
cation of the Y-chromosome allele at DYZ1 locus enhanced the
sensitivity of detection to less than 1% of host DNA. Lineage
speciﬁc chimaerism was analysed as single lineage mixed chimae-
rism was seen in some patients, mainly in the non myeloablative
setting. Both VNTR and STR gave concordant results in most
samples (	95%) analysed although the sensitivity of the VNTR
assay was approximately 5% while the STR was 10%. There were
2 recipients where VNTR was able to detect the presence of mixed
chimaerism earlier than STR and this proved to correlate clinically
with disease relapse in the patients later. The presence of full donor
chimaerism correlated well with continuing complete remission
although frank disease relapse did occur even in complete donor
chimaerism detected up to 2 weeks earlier. The presence of mixed
chimaerism has also helped guide administration of donor lympho-
cyte infusions with full chimerism obtained post DLI and continu-
ing remission. This study shows that chimaerism detection by
VNTR or STR is comparable and when loci are well selected,
VNTR can prove to be even more sensitive. More importantly,
this method is more cost-effective and equally effective compared
to STR to warrant its use in routine clinical settings. Although not
fully predictive of relapse in all situations, good correlation with
clinical remission/relapse was seen in this cohort of patients.
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STABLE DONOR ENGRAFTMENT FOLLOWING REDUCED INTENSITY
HEMATOPOIETIC CELL TRANSPLANTATION FOR SICKLE CELL DISEASE
Krishnamurti, L.1, Wu, C.J.2, Baker, S.3, Wagner, J.3 1. Children’s
Hospital of Pittsburgh, Pittsburgh, PA; 2. Dana Farber Cancer Institute,
Boston, MA; 3. University of Minnesota, Minneapolis, MN.
Objective: Hematopoietic cell transplantation (HCT) from sib-
ling donors has been demonstrated to cure hemoglobinopathies
such as sickle cell disease (SCD) and thalassemia. Concerns about
high regimen related toxicity (RRT) have prevented the use of
HCT in older patients, those with advanced organ damage or those
without a HLA matched related donor. Also, potential for late
sequelae such as chronic graft-versus-host disease (GVHD) and
infertility have limited the acceptance of this treatment even by
eligible patients. HCT following a reduced intensity conditioning
(RIC) regimen has the potential for reducing toxicity and poten-
tially making this curative therapy more acceptable and applicable
to this group of patients. Method: We initiated a pilot study to
evaluate the safety and efﬁcacy of HCT following a RIC regimen
for patients with high risk hemoglobinopathies. We report stable
long term engraftment with amelioration of clinical phenotype in
the ﬁrst ﬁve patients with SCD receiving unmodiﬁed bone marrow
from a matched sibling donor, on this study. The conditioning
regimen consisted of busulfan 2 mg/kg orally q12 hr  2 days (0.8
mg/kg IV q 6 hr  2 days for patient #3), ﬂudarabine 35 mg/m2/
dose IV daily  5 days, antithymocyte globulin 30 mg/kg/dose IV
daily  5 days and total lymphoid irradiation administered as a
single fraction of 500 cGy with shielding of the liver, lungs, heart,
and gonads. Prophylaxis for GVHD consisted of cyclosporine A
and mycophenolate mofetil. Results: Clinical characteristics and
outcomes of subjects are summarized in Table 1. The preparative
regimen was well tolerated with no serious infections or mucositis
in any patient. All patients are free of sickle cell disease and have
normal hemoglobin levels. No patient has had recurrence of pre-
vious sickle cell related symptoms. Lineage-speciﬁc chimerism
analysis (patients #3, 4, 5) revealed predominance of donor eryth-
ropoiesis even in the setting of residual recipient cellular engraft-
ment. These ﬁndings indicate that HCT for sickle cell disease
following a RIC regimen is well tolerated and can lead to stable
long term engraftment (Table 1).
Table 1. Clinical Characteristics and Outcomes of Patients with













D  100 D  180 D  360
1. 8 yrs. stroke,
allosensitization
2200 None 7 None 89 100 100
2. 8 yrs. repeated
ACS
1800 None 8 Grade
II Skin
75 81 81
3. 6 yrs. repeated
ACS, silent
infarct
800 None 9 None 75/30/100 85/35/100 81/45/100
4. 8 years repeated
ACS
350 None 14 None 79/30/100 71/58/100 —
5. 18 yrs stroke,
allosensitization,
345 Mild 13 None 100/100/100 100/100/100 —
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